MLchartDataset catalogue

Sirexatamab

Term · Oncology and biomedicine · MLC-T-ONC-016750

A humanized monoclonal antibody directed against the WNT antagonist dickkopf homolog 1 (DKK1), with potential anti-osteolytic activity. Upon administration, sirexatamab binds to and inhibits DKK1, thereby restoring signaling through the WNT pathway, which may result in osteoblast differentiation and activation within the bone matrix and the reversal of tumor-induced osteolytic disease. DKK1, overexpressed by certain cancer cells, is an inhibitor of the WNT signaling pathway and prevents the mediated formation of bone.

Table 1. Record
IdentifierMLC-T-ONC-016750
FieldOncology and biomedicine
SynonymsDKK1-neutralizing monoclonal antibody DKN-01
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-016750",
  "term": "Sirexatamab",
  "field": "Oncology and biomedicine",
  "definition": "A humanized monoclonal antibody directed against the WNT antagonist dickkopf homolog 1 (DKK1), with potential anti-osteolytic activity. Upon administration, sirexatamab binds to and inhibits DKK1, thereby restoring signaling through the WNT pathway, which may result in osteoblast differentiation and activation within the bone matrix and the reversal of tumor-induced osteolytic disease. DKK1, overexpressed by certain cancer cells, is an inhibitor of the WNT signaling pathway and prevents the mediated formation of bone.",
  "synonyms": [
    "DKK1-neutralizing monoclonal antibody DKN-01"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/sirexatamab/"
}

Record 15,025 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.